S2k guideline on the treatment of acne;S2k-Leitlinie zur Therapie der Akne: Leitlinie zur Therapie der Akne

JDDG - Journal of the German Society of Dermatology

Volumn 8, Issue SUPPL. 2, 2010, Pages

  Nast, Alexander ^a   Bayerl, Christiane ^b   Borelli, Claudia ^c   Degitz, Klaus ^d   Dirschka, Thomas ^e   Erdmann, Ricardo ^a   Fluhr, Joachim ^a   Gieler, Uwe ^f   Hartwig, Roland ^g   Meigel, Eva Maria ^h   Möller, Siegfried ⁱ   Ochsendorf, Falk ^j   Podda, Maurizio ^k   Rabe, Thomas ^l   Rzany, Berthold ^a   Sammain, Adel ^a   Schink, Susanne ^a   Zouboulis, Christos C ^a   Gollnick, Harald ^m  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Wilhelm Fresenius Klinik   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Niedergelassener Dermatologe   (Germany)

^e Niedergelassener Dermatologe   (Germany)

^f JUSTUS LIEBIG UNIVERSITY   (Germany)

^g Niedergelassener Dermatologe   (Germany)

^h Niedergelassene Dermatologin   (Germany)

ⁱ Niedergelassener Dermatologe   (Germany)

^j UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^k KLINIKUM DARMSTADT   (Germany)

^l UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^m OTTO VON GUERICKE UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; BENZOYL PEROXIDE; CHLORHEXIDINE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; CYANOCOBALAMIN; DOXYCYCLINE; ERYTHROMYCIN; GLUCOCORTICOID; ISOTRETINOIN; MACROLIDE; MICONAZOLE; MINOCYCLINE; NADIFLOXACIN; OXYTETRACYCLINE; PENICILLAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENOL; PYRIDOXINE; QUINOLONE; RESORCINOL; RETINOIC ACID; RETINOID DERIVATIVE; TETRACYCLINE; THIOURACIL; TRICLOSAN; UNINDEXED DRUG; ZINC; ZINC ACETATE;

ACNE; ACNE CONGOBATA; ACNE PAPULO PUSTULOSA NODOSA; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; COMEDONAL ACNE; DIFFERENTIAL DIAGNOSIS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; ESOPHAGITIS; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; GENDER; GENETICS; GERMANY; HUMAN; HYPERPIGMENTATION; LACTATION; LIPOGENESIS; LUPUS ERYTHEMATOSUS; MAINTENANCE THERAPY; MEDICAL SOCIETY; MONOTHERAPY; PANCREATITIS; PAPULAR PUSTULAR ACNE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHOTOTOXICITY; PRACTICE GUIDELINE; PREGNANCY; PROPIONIBACTERIUM ACNES; PSEUDOMEMBRANOUS COLITIS; QUALITY OF LIFE; REVIEW; SCAR FORMATION; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VAGINA CANDIDIASIS;

ACNE VULGARIS; ADULT; DERMATOLOGY; FEMALE; GERMANY; HUMANS; LACTATION; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 77954132778     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2010.07466.x     Document Type: Review

References (477)

1. AWMF. The Guideline Manual. Development and implementation of guidelines in medicine. Z Arztl Fortbild Qualitatssich. 2001; 95 Suppl 1:1-84.
2. Franzke N, Zimmer L, Schafer I, Radermacher C, Kresken J, Augustin M. Quality of medical care of patients with acne vulgaris in Germany - nationwide survey of pharmacy clients. J Dtsch Dermatol Ges. 2009; 7: 1060-1063
3. Schaefer I, Rustenbach SJ, Zimmer L, Augustin M. Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology. 2008; 217:169-172
4. Ghodsi SZ, Orawa H, Zouboulis CC. Prevalence, Severity, and Severity Risk Factors of Acne in High School Pupils: A Community-Based Study. J Invest Dermatol. 2009.
5. Rzany B, Kahl C. Epidemiology of acne vulgaris. J Dtsch Dermatol Ges. 2006; 4: 8-9.
6. Tan JK. Psychosocial impact of acne vulgaris: evaluating the evidence. Skin Therapy Lett. 2004; 9: 1-3, 9.
7. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999; 140: 672-676
8. Serup J, Lindblad AK, Maroti M, Kjellgren KI, Niklasson E, Ring L, Ahlner J. To follow or not to follow dermatological treatment - a review of the literature. Acta dermato-venereologica. 2006; 86: 193-197
9. Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol. 2004; 22: 360-366
10. Nijsten T, Rombouts S, Lambert J. Acne is prevalent but use of its treatments is infrequent among adolescents from the general population. J Eur Acad Dermatol Venereol. 2007;21: 163-168
11. Uslu G, Sendur N, Uslu M, Savk E, Karaman G, Eskin M. Acne: prevalence, perceptions and effects on psychological health among adolescents in Aydin, Turkey. J Eur Acad Dermatol Venereol. 2008; 22: 462-469
12. Burton JL, Cunliffe WJ, Stafford I, Shuster S. The prevalence of acne vulgaris in adolescence. Br J Dermatol. 1971; 85: 119-126
13. Gloor M, Eicher C, Wiebelt H, Moser G. Sociologic studies in acne vulgaris. 1. Disease significance of acne vulgaris. Zeitschrift fur Hautkrankheiten. 1978; 53: 871-880
14. Gotz H, Zabel G. Acne vulgaris in 2,249 high-school students in the 12-20 years age group. G Ital Dermatol Minerva Dermatol. 1971; 46: 133-136
15. Jemec GB, Linneberg A, Nielsen NH, Frolund L, Madsen F, Jorgensen T. Have oral contraceptives reduced the prevalence of acne? A populationbased study of acne vulgaris, tobacco smoking and oral contraceptives. Dermatology. 2002; 204: 179-184
16. Kilkenny M, Stathakis V, Hibbert ME, Patton G, Caust J, Bowes G. Acne in Victorian adolescents: associations with age, gender, puberty and psychiatric symptoms. J Paediatr Child Health. 1997; 33: 430-433
17. Rademaker M, Garioch JJ, Simpson NB. Acne in schoolchildren: no longer a concern for dermatologists. BMJ. Clinical research ed. 1989; 298:1217-1219
18. Schafer T, Nienhaus A, Vieluf D, Berger J, Ring J. Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol. 2001; 145: 100-104
19. Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. BMJ. 1979; 1: 1109-1110
20. Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol. 2001; 15: 541-545
21. Zouboulis CC, Eady A, Philpott M, Goldsmith LA, Orfanos C, Cunliffe WC, Rosenfield R. What is the pathogenesis of acne? Exp Dermatol.2005; 14: 143-152
22. Zouboulis CC. Moderne Aknetherapie. Akt Dermatol. 2003; 29: 49-57.
23. Zouboulis CC. Acne: Current aspects on pathology and treatment. Dermatol Experiences. 1999; 1: 6-37.
24. Chiu A, Chon SY, Kimball AB. The response of skin disease to stress: changes in the severity of acne vulgaris as affected by examination stress. Arch Dermatol. 2003; 139: 897-900.
25. Zouboulis CC, Bohm M. Neuroendocrine regulation of sebocytes - a pathogenetic link between stress and acne. Exp Dermatol. 2004; 13 Suppl 4: 31-35
26. Melnik BC. Milk - the promoter of chronic Western diseases. Med Hypotheses. 2009; 72: 631-639
27. Green J, Sinclair RD. Perceptions of acne vulgaris in final year medical student written examination answers. Australas J Dermatol. 2001; 42: 98-101.
28. Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, Xia L, Chen W, Nagy I, Picardo M, Suh DH, Ganceviciene R, Schagen S, Tsatsou F, Zouboulis CC. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009.
29. Herane MI, Ando I. Acne in infancy and acne genetics. Dermatology. 2003; 206: 24-28
30. Goulden V, McGeown CH, Cunliffe WJ. The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals.Br J Dermatol. 1999; 141:297-300.
31. Walton S, Wyatt EH, Cunliffe WJ. Genetic control of sebum excretion and acne - a twin study. Br J Dermatol. 1988; 118: 393-396
32. Kirk KM, Evans DM, Farthing B, Martin NG. Genetic and environmental influences on acne in adolescent twins. Twin Res. 2001; 4: 190.
33. Bekaert C, Song M, Delvigne A. Acne neonatorum and familial hyperandrogenism. Dermatology. 1998; 196:453-454
34. Ostlere LS, Rumsby G, Holownia P, Jacobs HS, Rustin MH, Honour JW. Carrier status for steroid 21-hydroxylase deficiency is only one factor in the variable phenotype of acne. Clin Endocrinol (Oxf ). 1998; 48: 209-215
35. Bataille V, Snieder H, MacGregor AJ, Sasieni P, Spector TD. The influence of genetics and environmental factors in the pathogenesis of acne: a twin study of acne in women. J Invest Dermatol. 2002; 119: 1317-1322
36. Stewart ME, Grahek MO, Cambier LS, Wertz PW, Downing DT. Dilutional effect of increased sebaceous gland activity on the proportion of linoleic acid in sebaceous wax esters and in epidermal acylceramides. J Invest Dermatol. 1986;87: 733-736
37. Pochi PE, Strauss JS. Sebaceous gland response in man to the administration of testosterone, delta-4-androstenedione, and dehydroisoandrosterone. J Invest Dermatol. 1969;52: 32-36
38. Gollnick HP, Zouboulis CC, Akamatsu H, Kurokawa I, Schulte A. Pathogenesis and pathogenesis related treatment of acne. J Dermatol. 1991;18: 489-499
39. Chen W, Yang CC, Liao CY, Hung CL, Tsai SJ, Chen KF, Sheu HM, Zouboulis CC. Expression of sex-determining genes in human sebaceous glands and their possible role in the pathogenesis of acne. J Eur Acad Dermatol Venereol. 2006; 20: 846-852
40. Cunliffe W, Forster R. Androgen control of the pilosebaceous duct? Br J Dermatol. 1987; 116: 449.
41. Zouboulis CC. The sebaceous gland in adolescent age. Eur J Ped Dermatol. 2008; 18: 150-154
42. Thiboutot D, Knaggs H, Gilliland K, Lin G. Activity of 5-alpha-reductase and 17-beta-hydroxysteroid dehydrogenase in the infrainfundibulum of subjects with and without acne vulgaris. Dermatology. 1998; 196: 38-42.
43. Lucky AW, Biro FM, Huster GA, Leach AD, Morrison JA, Ratterman J. Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol. 1994; 130:308-314
44. Stewart ME, Downing DT, Cook JS, Hansen JR, Strauss JS. Sebaceous gland activity and serum dehydroepiandrosterone sulfate levels in boys and girls. Arch Dermatol. 1992; 128:1345-1348
45. Marynick SP, Chakmakjian ZH, McCaffree DL, Herndon JH, Jr. Androgen excess in cystic acne. N Engl J Med. 1983; 308: 981-986
46. Schmidt JB, Spona J, Huber J. Androgen receptor in hirsutism and acne. Gynecol Obstet Invest. 1986; 22:206-211
47. Thiboutot D, Harris G, Iles V, Cimis G, Gilliland K, Hagari S. Activity of the type 1 5-alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol. 1995; 105: 209-214
48. Zouboulis CC. Therapie der Akne mit Antiandrogenen - Eine evidenzbasierte Übersicht. J Dtsch Dermatol Ges. 2003; 1: 535-546
49. Imperato-McGinley J, Gautier T, Cai LQ, Yee B, Epstein J, Pochi P. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab. 1993; 76: 524-528
50. Rosenfield RL, Deplewski D, Kentsis A, Ciletti N. Mechanisms of androgen induction of sebocyte differentiation. Dermatology. 1998; 196:43-46
51. Makrantonaki E, Zouboulis CC. Testosterone metabolism to 5-alphadihydrotestosterone and synthesis of sebaceous lipids is regulated by the peroxisome proliferator-activated receptor ligand linoleic acid in human sebocytes. Br J Dermatol. 2007; 156:428-432
52. Fimmel S, Saborowski A, Terouanne B, Sultan C, Zouboulis CC. Inhibition of the androgen receptor by antisense oligonucleotides regulates the biological activity of androgens in SZ95 sebocytes. Horm Metab Res. 2007; 39: 149-156
53. Alestas T, Ganceviciene R, Fimmel S, Muller-Decker K, Zouboulis CC. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med. 2006; 84: 75-87.
54. Chen W, Yang CC, Sheu HM, Seltmann H, Zouboulis CC. Expression of peroxisome proliferator-activated receptor and CCAAT/enhancer binding protein transcription factors in cultured human sebocytes. J Invest Dermatol. 2003; 121: 441-447
55. Wrobel A, Seltmann H, Fimmel S, Muller-Decker K, Tsukada M, Bogdanoff B, Mandt N, Blume-Peytavi U, Orfanos CE, Zouboulis CC. Differentiation and apoptosis in human immortalized sebocytes. J Invest Dermatol. 2003; 120: 175-181
56. Zouboulis CC, Nestoris S, Adler YD, Orth M, Orfanos CE, Picardo M, Camera E, Cunliffe WJ. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch Dermatol. 2003; 139:668-670
57. Zouboulis CC, Saborowski A, Boschnakow A. Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. Dermatology. 2005; 210: 36-38
58. Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, Sivarajah S, Gilliland KL, Liu W, Mauger DT, Gabbay RA, Thiboutot DM. Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol. 2006; 126: 2002-2009
59. Norris JF, Cunliffe WJ. A histological and immunocytochemical study of early acne lesions. Br J Dermatol. 1988; 118: 651-659
60. Cunliffe WJ, Holland DB, Clark SM, Stables GI. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol.2000; 142: 1084-1091
61. Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol.2003; 121: 20-27
62. Zouboulis CC. Is acne vulgaris a genuine inflammatory disease? Dermatology. 2001; 203: 277-279
63. Ingham E, Eady EA, Goodwin CE, Cove JH, Cunliffe WJ. Pro-inflammatory levels of interleukin-1 alphalike bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol. 1992; 98:895-901.
64. Zouboulis CC, Xia L, Akamatsu H, Seltmann H, Fritsch M, Hornemann S, Ruhl R, Chen W, Nau H, Orfanos CE. The human sebocyte culture model provides new insights into development and management of seborrhea and acne. Dermatology. 1998;196: 21-31.
65. Anttila HS, Reitamo S, Saurat JH. Interleukin 1 immunoreactivity in sebaceous glands. Br J Dermatol. 1992; 127: 585-588
66. Boehm KD, Yun JK, Strohl KP, Elmets CA. Messenger RNAs for the multifunctional cytokines interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor-alpha are present in adnexal tissues and in dermis of normal human skin. Exp Dermatol.1995; 4: 335-341
67. Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol. 1996; 106: 176-182
68. Toyoda M, Nakamura M, Makino T, Kagoura M, Morohashi M. Sebaceous glands in acne patients express high levels of neutral endopeptidase. Exp Dermatol. 2002;11: 241-247
69. Thielitz A, Reinhold D, Vetter R, Bank U, Helmuth M, Hartig R, Wrenger S, Wiswedel I, Lendeckel U, Kahne T, Neubert K, Faust J, Zouboulis CC, Ansorge S, Gollnick H. Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation. J Invest Dermatol. 2007; 127: 1042-1051
70. Zouboulis CC, Seltmann H, Hiroi N, Chen W, Young M, Oeff M, Scherbaum WA, Orfanos CE, Mc-Cann SM, Bornstein SR. Corticotropin-releasing hormone: an autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci U S A. 2002; 99: 7148-7153
71. Krause K, Schnitger A, Fimmel S, Glass E, Zouboulis CC. Corticotropin-releasing hormone skin signaling is receptor-mediated and is predominant in the sebaceous glands. Horm Metab Res. 2007; 39: 166-170
72. Ganceviciene R, Graziene V, Fimmel S, Zouboulis CC. Involvement of the corticotropin-releasing hormone system in the pathogenesis of acne vulgaris.Br J Dermatol. 2009; 160:345-352
73. Alesci S, Bornstein SR. Neuroimmunoregulation of androgens in the adrenal gland and the skin. Horm Res. 2000; 54: 281-286
74. Slominski AT, Botchkarev V, Choudhry M, Fazal N, Fechner K, Furkert J, Krause E, Roloff B, Sayeed M, Wei E, Zbytek B, Zipper J, Wortsman J, Paus R. Cutaneous expression of CRH and CRH-R. Is there a "skin stress response system?" Ann N Y Acad Sci. 1999; 885: 287-311.
75. Zouboulis CC. The human skin as a hormone target and an endocrine gland. Hormones (Athens). 2004; 3:9-26.
76. Letawe C, Boone M, Pierard GE. Digital image analysis of the effect of topically applied linoleic acid on acne microcomedones. Clinical and Exp Dermatol. 1998; 23: 56-58
77. Zhang Q, Seltmann H, Zouboulis CC, Konger RL. Involvement of PPARgamma in oxidative stress-mediated prostaglandin E(2) production in SZ95 human sebaceous gland cells. J Invest Dermatol. 2006; 126: 42-48
78. Schaefer O. When the Eskimo comes to town. Nutr Today. 1971; 6: 8-16.
79. Steiner PE. Necropsies on Okinawans: anatomic and pathologic observations.Arch Pathol. 1946; 42: 359-380
80. Simopoulos AP. Evolutionary aspects of diet and essential fatty acids. World Rev Nutr Diet. 2001; 88: 18-27.
81. Adebamowo CA, Spiegelman D, Berkey CS, Danby FW, Rockett HH, Colditz GA, Willett WC, Holmes MD. Milk consumption and acne in teenaged boys. J Am Acad Dermatol. 2008; 58: 787-793
82. Smith RN, Mann NJ, Braue A, Makelainen H, Varigos GA. A low-glycemic- load diet improves symptoms in acne vulgaris patients: a randomized controlled trial. Am J Clin Nutr. 2007; 86: 107-115
83. Cordain L, Lindeberg S, Hurtado M, Hill K, Eaton SB, Brand-Miller J. Acne vulgaris: a disease of Western civilization. Arch Dermatol. 2002; 138: 1584-1590
84. Thiboutot DM, Strauss JS. Diet and acne revisited. Arch Dermatol. 2002;138: 1591-1592
85. Firooz A, Sarhangnejad R, Davoudi SM, Nassiri-Kashani M. Acne and smoking: is there a relationship? BMC Dermatol. 2005; 5: 2.
86. Galobardes B, Davey Smith G, Jeffreys M, Kinra S, McCarron P. Acne in adolescence and cause-specific mortality: lower coronary heart disease but higher prostate cancer mortality: the Glasgow Alumni Cohort Study. Am J Epidemiol. 2005; 161: 1094-1101
87. Klaz I, Kochba I, Shohat T, Zarka S, Brenner S. Severe acne vulgaris and tobacco smoking in young men. J Invest Dermatol. 2006; 126: 1749-1752
88. Tithof PK, Elgayyar M, Cho Y, Guan W, Fisher AB, Peters-Golden M. Polycyclic aromatic hydrocarbons present in cigarette smoke cause endothelial cell apoptosis by a phospholipase A2-dependent mechanism. FASEB J. 2002; 16: 1463-1464
89. Zouboulis CC. Human skin: an independent peripheral endocrine organ. Horm Res. 2000; 54: 230-242
90. Thompson RL, Pyke S, Scott EA, Thompson SG, Wood DA. Cigarette smoking, polyunsaturated fats, and coronary heart disease. Ann N Y Acad Sci. 1993; 686: 130-8; discussion 38-39
91. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, Legaspi AJ, Brightbill HD, Holland D, Cunliffe WJ, Akira S, Sieling PA, Godowski PJ, Modlin RL. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002; 169: 1535-1541
92. Pivarcsi A, Bodai L, Rethi B, Kenderessy-Szabo A, Koreck A, Szell M, Beer Z, Bata-Csorgoo Z, Magocsi M, Rajnavolgyi E, Dobozy A, Kemeny L. Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int Immunol.2003; 15: 721-730
93. Ingham E, Walters CE, Eady EA, Cove JH, Kearney JN, Cunliffe WJ. Inflammation in acne vulgaris: failure of skin micro-organisms to modulate keratinocyte interleukin 1 alpha production in vitro. Dermatology. 1998;196: 86-88
94. Schaller M, Loewenstein M, Borelli C, Jacob K, Vogeser M, Burgdorf WH, Plewig G. Induction of a chemoattractive proinflammatory cytokine response after stimulation of keratinocytes with Propionibacterium acnes and coproporphyrin III. Br J Dermatol. 2005; 153: 66-71.
95. Oeff MK, Seltmann H, Hiroi N, Nastos A, Makrantonaki E, Bornstein SR, Zouboulis CC. Differential regulation of Toll-like receptor and CD14 pathways by retinoids and corticosteroids in human sebocytes. Dermatology. 2006; 213: 266.
96. Seltmann H, Zouboulis Ch C. Human sebocytes express CD14 molecules and their IL8 production is induced by both CD14-dependent and independent pathways. J Invest Dermatol. 2001; 117: 804.
97. Georgel P, Crozat K, Lauth X, Makrantonaki E, Seltmann H, Sovath S, Hoebe K, Du X, Rutschmann S, Jiang Z, Bigby T, Nizet V, Zouboulis CC, Beutler B. A toll-like receptor 2-responsive lipid effector pathway protects mammals against skin infections with gram-positive bacteria. Infect Immun. 2005; 73: 4512-4521
98. Nagy I, Pivarcsi A, Kis K, Koreck A, Bodai L, McDowell A, Seltmann H, Patrick S, Zouboulis CC, Kemeny L. Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect.2006; 8: 2195-2205
99. Lee DY, Yamasaki K, Rudsil J, Zouboulis CC, Park GT, Yang JM, Gallo RL. Sebocytes express functional cathelicidin antimicrobial peptides and can act to kill propionibacterium acnes. J Invest Dermatol. 2008; 128: 1863-1866
100. Ganceviciene R, Fimmel S, Glass E, Zouboulis CC. Psoriasin and follicular hyperkeratinization in acne comedones. Dermatology. 2006; 213:270-272
101. Plewig G, Kligman AM. Acneiform diseases. In: Plewig G, Kligman AM: Acne and Rosacea. 3rd edition ed. Berlin, Heidelberg, New York: Springer Verlag, 2000. 431-455 ISBN:3540667512.
102. Levy A, Feuilhade de Chauvin M, Dubertret L, Morel P, Flageul B. Malassezia folliculitis: characteristics and therapeutic response in 26 patients. Ann Dermatol Venerol. 2007; 134: 823-828
103. Back O, Faergemann J, Hornqvist R. Pityrosporum folliculitis: a common disease of the young and middleaged. J Am Acad Dermatol. 1985; 12:56-61.
104. Hsu CK, Hsu MM, Lee JY. Demodicosis: a clinicopathological study. J Am Acad Dermatol. 2009; 60: 453-462
105. Plewig G. Akne und Rosazea. In: Braun-Falco O, Plewig G, Wolff HH, Burgdorf WC, Landthaler M: Dermatologie und Venerologie. Heidelberg: Springer Verlag, 2005. 885-900. ISBN: 3540405259.
106. Neubert U, Jansen T, Plewig G. Bacteriologic and immunologic aspects of gram-negative folliculitis: a study of 46 patients. Int J Dermatol. 1999; 38: 270-274
107. Plewig G, Kligman AM. Gramnegative folliculitis. In: Plewig G, Kligman AM: Acne and Rosacea. 3rd edition ed. Berlin, Heidelberg, New York: Springer Verlag, 2000. 513-19.ISBN: 3540667512.
108. Budavari JM, Grayson W. Papular follicular eruptions in human immunodeficiency virus-positive patients in South Africa. Int J Dermatol. 2007; 46: 706-710
109. Schöfer H, Ochsendorf F. HIV-assoziierte Haut- und Schleimhauterkrankungen. In: Hoffmann C, Rockstroh J, Kamps BS: HIVNet 2008. Wuppertal: Steinhäuser Verlag, 2008.595-616 ISBN: 3924774609.
110. Akamatsu H, Zouboulis CC, Orfanos CE. Control of human sebocyte proliferation in vitro by testosterone and 5-alpha-dihydrotestosterone is dependent on the localization of the sebaceous glands. J Invest Dermatol. 1992; 99: 509-511
111. Zouboulis CC, Chen WC, Thornton MJ, Qin K, Rosenfield R. Sexual hormones in human skin. Horm Metab Res. 2007; 39: 85-95.
112. Orfanos CE, Adler YD, Zouboulis CC. The SAHA syndrome. Horm Res. 2000; 54: 251-258
113. Chen W, Zouboulis Ch C. Hormones and the pilosebaceous unit. Dermato- Endocrinology. 2009; 1: 81-86.
114. Zouboulis CC, Degitz K. Androgen action on human skin - from basic research to clinical significance. Exp Dermatol. 2004; 13 Suppl 4: 5-10.
115. Leyden JJ, James WD. Staphylococcus aureus infection as a complication of isotretinoin therapy. Arch Dermatol.1987; 123: 606-608
116. Coates P, Vyakrnam S, Eady EA, Jones CE, Cove JH, Cunliffe WJ. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol. 2002; 146: 840-848
117. Dalgard F, Gieler U, Holm JO, Bjertness E, Hauser S. Self-esteem and body satisfaction among late adolescents with acne: results from a population survey. J Am Acad Dermatol. 2009; 59: 746-751
118. Krejci-Manwaring J, Kerchner K, Feldman SR, Rapp DA, Rapp SR. Social sensitivity and acne: the role of personality in negative social consequences and quality of life. Int J Psychiatry Med. 2006; 36: 121-130
119. Loney T, Standage M, Lewis S. Not just skin deep: psychosocial effects of dermatological-related social anxiety in a sample of acne patients. J Health Psychol. 2008; 13: 47-54.
120. Pawin H, Chivot M, Beylot C, Faure M, Poli F, Revuz J, Dreno B. Living with acne. A study of adolescents personal experiences. Dermatology. 2007; 215: 308-314
121. Quandt SA, Schulz MR, Vallejos QM, Feldman SR, Verma A, Fleischer AB, Rapp SR, Arcury TA. The association of dermatologist-diagnosed and self-reported skin diseases with skin-related quality of life in Latino migrant farmworkers. Int J Dermatol. 2008; 47: 236-241
122. Demircay Z, Seckin D, Senol A, Demir F. Patients perspective: an important issue not to be overlooked in assessing acne severity. Eur J Dermatol. 2008; 18: 181-184
123. Dreno B, Alirezai M, Auffret N, Beylot C, Chivot M, Daniel F, Faure M, Lambert D, Poli F, Merial-Kieny C, Nocera T. Clinical and psychological correlation in acne: use of the ECLA and CADI scales. Ann Dermatol Venerol. 2007; 134: 451-455
124. Law MP, Chuh AA, Lee A, Molinari N. Acne prevalence and beyond: acne disability and its predictive factors among Chinese late adolescents in Hong Kong. Clinical and Exp Dermatol. 2009.
125. Tan JK, Li Y, Fung K, Gupta AK, Thomas DR, Sapra S, Lynde C, Poulin Y, Gulliver W, Sebaldt RJ. Divergence of demographic factors associated with clinical severity compared with quality of life impact in acne. J Cutan Med Surg. 2008; 12: 235-242
126. Yolac Yarpuz A, Demirci Saadet E, Erdi Sanli H, Devrimci Ozguven H. Social anxiety level in acne vulgaris patients and its relationship to clinical variables. Turk Psikiyatri Derg. 2008; 19: 29-37.
127. Hahm BJ, Min SU, Yoon MY, Shin YW, Kim JS, Jung JY, Suh DH. Changes of psychiatric parameters and their relationships by oral isotretinoin in acne patients. J Dermatol. 2009; 36: 255-261
128. Kaymak Y, Taner E, Taner Y. Comparison of depression, anxiety and life quality in acne vulgaris patients who were treated with either isotretinoin or topical agents. Int J Dermatol.2009; 48: 41-46
129. Yentzer BA, Alikhan A, Teuschler H, Williams LL, Tusa M, Fleischer AB, Jr., Kaur M, Balkrishnan R, Feldman SR. An exploratory study of adherence to topical benzoyl peroxide in patients with acne vulgaris. J Am Acad Dermatol. 2009; 60: 879-880
130. Zaghloul SS, Cunliffe WJ, Goodfield MJ. Objective assessment of compliance with treatments in acne. Br J Dermatol. 2005; 152: 1015-1021
131. Niemeier V, Kupfer J, Demmelbauer-Ebner M, Stangier U, Effendy I, Gieler U. Coping with acne vulgaris. Evaluation of the chronic skin disorder questionnaire in patients with acne. Dermatology. 1998; 196:108-115
132. Thiboutot D, Dreno B, Layton A. Acne counseling to improve adherence. Cutis; cutaneous medicine for the practitioner. 2008; 81: 81-86
133. Davies E, Patel C, Salek MS, Finlay AY. Does ad hoc quality-of-life discussion in inflammatory skin disease consultations reflect standardized patient-reported outcomes? Clinical and Exp Dermatol. 2008; 33: 16-21.
134. Jones-Caballero M, Pedrosa E, Penas PF. Self-reported adherence to treatment and quality of life in mild to moderate acne. Dermatology. 2008; 217: 309-314
135. Pawin H, Beylot C, Chivot M, Faure M, Poli F, Revuz J, Dreno B. Creation of a tool to assess adherence to treatments for acne. Dermatology. 2009; 218: 26-32.
136. Draelos ZK. Patient compliance: enhancing clinician abilities and strategies. J Am Acad Dermatol. 1995; 32: S42-8.
137. Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? : implications of resistance for acne patients and prescribers. Am J Clin Dermatol. 2003; 4: 813-831
138. Fluhr JW, Gloor M, Dietz P, Hoffler U. In Vitro activity of 6 antimicrobials against propionibacteria isolates from untreated acne papulopustulosa. Zentralbl Bakteriol. 1999; 289: 53-61.
139. Ross JI, Eady EA, Cove JH, Ratyal AH, Cunliffe WJ. Resistance to erythromycin and clindamycin in cutaneous propionibacteria is associated with mutations in 23S rRNA. Dermatology. 1998; 196: 69-70.
140. Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, Tosti G, Katsambas A, Galvan Perez Del Pulgar JI, Rollman O, Torok L, Eady EA, Cove JH. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol. 2003; 148: 467-478
141. Jones EL, Crumley AF. Topical erythromycin vs blank vehicle in a multiclinic acne study. Arch Dermatol. 1981; 117: 551-553
142. Perez Lopez M, Moragas Vinas JM. Nueva sal de eritromicina (A-137 o laurilsulfato de eritromicina) en el tratamiento topico del acne. Med Cutan Ibero Lat Am. 1982; 10:151-158
143. Prince RA, Busch DA, Hepler CD, Feldick HG. Clinical trial of topical erythromycin in inflammatory acne. Drug intelligence & clinical pharmacy. 1981; 15: 372-376
144. Christian GL, Krueger GG. Clindamycin vs placebo as adjunctive therapy in moderately severe acne. Arch Dermatol. 1975; 111: 997-1000.
145. Leyden JJ, Berger RS, Dunlap FE, Ellis CN, Connolly MA, Levy SF. Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. Am J Clin Dermatol.2001; 2: 33-39
146. Kurokawa I, Akamatsu H, Nishijima S, Asada Y, Kawabata S. Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a doubleblind group comparison study versus cream base. J Am Acad Dermatol.1991; 25: 674-681
147. Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream. Eur J Dermatol. 2006; 16: 48-55.
148. Anderson RL, Cook CH, Smith DE. The effect of oral and topical tetracycline on acne severity and on surface lipid composition. J Invest Dermatol. 1976; 66: 172-177
149. Blaney DJ, Cook CH. Topical use of tetracycline in the treatment of acne: a double-blind study comparing topical and oral tetracycline therapy and placebo. Arch Dermatol. 1976; 112:971-973
150. Toyoda M, Morohashi M. An overview of topical antibiotics for acne treatment. Dermatology. 1998; 196: 130-134
151. Panzer JD, Poche W, Meek TJ, Derbes VJ, Atkinson W. Acne treatment: a comparative efficacy trial of clindamycin and tetracycline. Cutis; cutaneous medicine for the practitioner. 1977; 19: 109-111
152. Langner A, Chu A, Goulden V, Ambroziak M. A randomized, singleblind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. Br J Dermatol. 2008; 158: 122-129
153. Hegemann L, Toso SM, Kitay K, Webster GF. Anti-inflammatory actions of benzoyl peroxide: effects on the generation of reactive oxygen species by leucocytes and the activity of protein kinase C and calmodulin. Br J Dermatol.1994; 130: 569-575
154. Thiele JJ. Oxidative targets in the stratum corneum. A new basis for antioxidative strategies. Skin Pharmacol Appl Skin Physiol. 2001; 14 Suppl 1:87-91.
155. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence- based medicine: How to practice and teach EBM. London: Churchill Livingstone, 2001. 169-182
156. Smith EB, Padilla RS, McCabe JM, Becker LE. Benzoyl peroxide lotion (20 percent) in acne. Cutis; cutaneous medicine for the practitioner. 1980;25: 90-92
157. Ozolins M, Eady EA, Avery AJ, Cunliffe WJ, Po AL, ONeill C, Simpson NB, Walters CE, Carnegie E, Lewis JB, Dada J, Haynes M, Williams K, Williams HC. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomized controlled trial. Lancet. 2004; 364: 2188-2195
158. Mills OH, Jr., Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol. 1986; 25: 664-667
159. Thiboutot D, Zaenglein A, Weiss J, Webster G, Calvarese B, Chen D. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the oncedaily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol. 2008; 59: 792-800.
160. Cunliffe WJ, Burke B. Benzoyl peroxide: lack of sensitization. Acta dermato-venereologica. 1982; 62: 458-459
161. Jeanmougin M, Pedreiro J, Bouchet J, Civatte J. Phototoxic activity of 5% benzoyl peroxide in man. Use of a new methodology. Dermatologica. 1983; 167: 19-23.
162. Fanta D, Scholz N. Miconazole-benzoyl peroxide: a new combination for extending the topical therapy of acne. Zeitschrift fur Hautkrankheiten.1984; 59: 873-881
163. Reinel D, Beierdorffer H. A new drug combination for the topical treatment of acne. Miconazole 2% + benzoyl peroxide 5% versus benzoyl peroxide 5% - a double-blind study. Zeitschrift fur Hautkrankheiten. 1985; 60: 648-50, 53-56
164. Beer P. Untersuchungen über die Wirkung der Vitamin-A-Säure. Dermatologica.1962; 124: 192-195
165. Stüttgen G. Zur Lokalbehandlung von Keratosen mit Vitamin A-Säure. Dermatologica. 1962; 124.
166. Krishnan G. Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris. The Practitioner. 1976; 216: 106-109
167. Christiansen J, Holm P, Reymann F. The retinoic acid derivative Ro 11-1430 in Acne vulgaris. A controlled multicenter trial against retinoic acid. Dermatologica. 1977; 154: 219-227
168. Webster GF. Safety and efficacy of Tretin-X compared with Retin-A in patients with mild-to-severe acne vulgaris. Skinmed. 2006; 5: 114-118
169. Lavker RM, Leyden JJ, Thorne EG. An ultrastructural study of the effects of topical tretinoin on microcomedones. Clinical therapeutics. 1992; 14:773-780
170. Berger R, Barba A, Fleischer A, Leyden JJ, Lucky A, Pariser D, Rafal E, Thiboutot D, Wilson D, Grossman R, Nighland M. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults. Cutis; cutaneous medicine for the practitioner.2007; 80: 152-157
171. Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol. 1998; 38: S17-23.
172. Mills OH, Jr., Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta dermato-venereologica. 1978;58: 555-557
173. Kreusch J, Bextermoller R. Efficacy and tolerability of a topical erythromycin/tretinoin combination preparation in acne treatment: postmarketing surveillance study involving over 6500 patients. Current medical research and opinion. 2000; 16: 1-7.
174. Korting HC, Braun-Falco O. Efficacy and tolerability of combined topical treatment of acne vulgaris with tretinoin and erythromycin in general practice. Drugs under experimental and clinical research. 1989; 15: 447-451
175. Gupta AK, Lynde CW, Kunynetz RA, Amin S, Choi K, Goldstein E. A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. J Cutan Med Surg. 2003; 7: 31-37
176. Handojo I. Retinoic acid cream (Airol cream) and benzoyl-peroxide in the treatment of acne vulgaris. The Southeast Asian journal of tropical medicine and public health. 1979; 10:548-551
177. Richter JR, Forstrom LR, Kiistala UO, Jung EG. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol. 1998;11: 227-233
178. Zouboulis CC, Derumeaux L, Decroix J, Maciejewska-Udziela B, Cambazard F, Stuhlert A. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol. 2000; 143: 498-505.
179. Schlessinger J, Menter A, Gold M, Leonardi C, Eichenfield L, Plott RT, Leyden J, Wortzman M. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol. 2007; 6: 607-615
180. Bowman S, Gold M, Nasir A, Vamvakias G. Comparison of clindamycin/ benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. J Drugs Dermatol.2005; 4: 611-618
181. Chalker DK, Lesher JL, Jr., Smith JG, Jr., Klauda HC, Pochi PE, Jacoby WS, Yonkosky DM, Voorhees JJ, Ellis CN, Matsuda-John S, et al. Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, double-blind investigation. J Am Acad Dermatol. 1987; 17: 251-254
182. Dominguez J, Hojyo MT, Celayo JL, Dominguez-Soto L, Teixeira F. Topical isotretinoin vs. topical retinoic acid in the treatment of acne vulgaris. Int J Dermatol. 1998; 37: 54-55
183. Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br J Dermatol. 2002; 147: 523-527
184. Hughes BR, Norris JF, Cunliffe WJ. A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clinical and Exp Dermatol. 1992; 17: 165-168
185. Glass D, Boorman GC, Stables GI, Cunliffe WJ, Goode K. A placebocontrolled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. Dermatology. 1999; 199: 242-247
186. Marazzi P, Boorman GC, Donald AE, Davies HD. Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. The Journal of dermatological treatment. 2002; 13: 111-117
187. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a metaanalysis of five randomized trials. Br J Dermatol. 1998; 139 Suppl 52: 48-56.
188. Thiboutot D, Gold MH, Jarratt MT, Kang S, Kaplan DL, Millikan L, Wolfe J, Loesche C, Baker M. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis; cutaneous medicine for the practitioner. 2001; 68: 10-19
189. Pierard-Franchimont C, Henry F, Fraiture AL, Fumal I, Pierard GE. Split-face clinical and bio-instrumental comparison of 0.1% adapalene and 0.05% tretinoin in facial acne. Dermatology. 1999; 198: 218-222
190. Cunliffe WJ, Danby FW, Dunlap F, Gold MH, Gratton D, Greenspan A. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris. Eur J Dermatol. 2002; 12: 350-354
191. Pariser DM, Thiboutot DM, Clark SD, Jones TM, Liu Y, Graeber M. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: A randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis; cutaneous medicine for the practitioner. 2005; 76:145-151
192. Wolf JE, Jr., Kaplan D, Kraus SJ, Loven KH, Rist T, Swinyer LJ, Baker MD, Liu YS, Czernielewski J. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol.2003; 49: S211-7.
193. Zhang JZ, Li LF, Tu YT, Zheng J. A successful maintenance approach in inflammatory acne with adapalene gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1%. The Journal of dermatological treatment. 2004; 15: 372-378
194. Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, Liu Y, Graeber M, Kang S. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007; 57: 791-799
195. Del Rosso JQ. Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. J Drugs Dermatol. 2007; 6:616-622
196. Gollnick H, Draelos Z, Glenn MJ. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, doubleblind, controlled study in 1670 patients. Br J Dermatol. in print.
197. Thiboutot D, Gollnick H, Stein-Gold L, Loesche C, Ma YM, Tan J. Adapalene 0.1 % and benzoyl peroxide 2.5 % demonstrate synergistics efficacy in the fixed-dose combination gel among 3855 acne vulgaris patients. Br J Dermatol.submitted.
198. Cunliffe WJ, Meynadier J, Alirezai M, George SA, Coutts I, Roseeuw DI, Hachem JP, Briantais P, Sidou F, Soto P. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol. 2003; 49: S218-26.
199. Brand B, Gilbert R, Baker MD, Poncet M, Greenspan A, Georgeian K, Soto P. Cumulative irritancy potential of adapalene cream 0.1% compared with adapalene gel 0.1% and several tretinoin formulations. Cutis; cutaneous medicine for the practitioner. 2003; 72: 455-458
200. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tretinoin microsphere 0.04% and 0.1%. Cutis; cutaneous medicine for the practitioner. 2005; 75: 238-243 (Pubitemid 40627632)
201. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1%. Cutis; cutaneous medicine for the practitioner. 2005; 75: 289-293 (Pubitemid 40826409)
202. Galvin SA, Gilbert R, Baker M, Guibal F, Tuley MR. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol. 1998; 139 Suppl 52:34-40.
203. Laquieze S, Czernielewski J, Rueda MJ. Beneficial effect of a moisturizing cream as adjunctive treatment to oral isotretinoin or topical tretinoin in the management of acne. J Drugs Dermatol. 2006; 5: 985-990
204. Latriano L, Tzimas G, Wong F, Wills RJ. The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of tretinoin and its metabolites after single doses or long-term use. J Am Acad Dermatol. 1997; 36: S37-46.
205. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet. 1993; 341: 1181-1182
206. Loureiro KD, Kao KK, Jones KL, Alvarado S, Chavez C, Dick L, Felix R, Johnson D, Chambers CD. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. American journal of medical genetics. 2005; 136: 117-121
207. Chen C, Jensen BK, Mistry G, Wyss R, Zultak M, Patel IH, Rakhit AK. Negligible systemic absorption of topical isotretinoin cream: implications for teratogenicity. Journal of clinical pharmacology. 1997; 37: 279-284
208. Autret E, Berjot M, Jonville-Bera AP, Aubry MC, Moraine C. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy. Lancet. 1997; 350: 339.
209. Nazzaro-Porro M, Passi S, Picardo M, Breathnach A, Clayton R, Zina G. Beneficial effect of 15% azelaic acid cream on acne vulgaris. Br J Dermatol. 1983; 109: 45-48
210. Zina G, Colonna S. The long-term treatment of acne with azelaic acid cream. J Dermatol Treat. 1989; 1 Suppl 1: 21-26 (Pubitemid 20375256)
211. Cavicchini S, Caputo R. Long-term treatment of acne with 20% azelaic acid cream. Acta Derm Venereol Suppl (Stockh). 1989; 143: 40-44 (Pubitemid 19172048)
212. Hjorth N, Graupe K. Azelaic acid for the treatment of acne. A clinical comparison with oral tetracycline. Acta Derm Venereol Suppl (Stockh). 1989; 143: 45-48 (Pubitemid 19172049)
213. Breathnach AS. A new agent in the treatment of acne: history, metabolism and biochemistry. J Dermatol Treat. 1989; 1 Suppl 1: 7-10.
214. Nazzaro-Porro M. Azelaic acid. J Am Acad Dermatol. 1987; 17: 1033-1041
215. Ortonne JP, Lacour JP. Evaluation de la phototoxicité de l acide azélaique par la méthode de Kadbey et Kligman. Nouvelles Dermatol. 1992; 2:490-495
216. Gollnick H. Azelainsäure. In: Korting HC, Sterry W: Therapeutische Verfahren in der Dermatologie: Blackwell Wissenschaftsverlag, 2001.253-264
217. Gollnick H. Die C9-Dicarbonsäure Azelainsäure als neue Substanz im Spektrum der Akne-Therapeutika. Dermatologische Monatschrift. 1992; 178: 143-152
218. Shibata M, Katsuyama M, Onodera T, Ehama R, Hosoi J, Tagami H. Glucocorticoids enhance Toll-like receptor 2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines. J Invest Dermatol. 2009;129: 375-382
219. Mahe A, Ly F, Aymard G, Dangou JM. Skin diseases associated with the cosmetic use of bleaching products in women from Dakar, Senegal. Br J Dermatol. 2003; 148: 493-500.
220. Nnoruka E, Okoye O. Topical steroid abuse: its use as a depigmenting agent. J Natl Med Assoc. 2006; 98: 934-939
221. Callender VD. Considerations for treating acne in ethnic skin. Cutis; cutaneous medicine for the practitioner. 2005; 76: 19-23.
222. Ad Hoc Committee report: systemic antibiotics for treatment of acne vulgaris: efficacy and safety. Arch Dermatol. 1975; 111: 1630-1636
223. Lehmann HP, Andrews JS. Management of Acne. Evidence Report/Technology Assessment No.17 (Prepared by John Hopkins Evidence-based Practice Center under Contract No. 290-97-006). Rockville, MD: Agency for Healthcare Research and Quality, 2001.
224. Garner SE, Eady EA, Popescu C, Newton J, Li WA. Minocycline for acne vulgaris: efficacy and safety. Cochrane database of systematic reviews (Online). 2003: CD002086.
225. Lehmann HP, Robinson KA, Andrews JS, Holloway V, Goodman SN. Acne therapy: a methodologic review. J Am Acad Dermatol. 2002; 47: 231-240
226. Dreno B, Bettoli V, Ochsendorf F, Layton A, Mobacken H, Degreef H. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004; 14: 391-399
227. Ochsendorf F. Systemic antibiotic therapy of acne vulgaris. J Dtsch Dermatol Ges. 2006; 4: 828-841
228. Simonart T, Dramaix M, De Maertelaer V. Efficacy of tetracyclines in the treatment of acne vulgaris: a review. Br J Dermatol. 2008; 158: 208-216
229. Campo M, Zuluaga A. A comparative study on the effectiveness of lymecicline and adapalene versus minocicline and adapalene in the treatment of acne vulgaris. Proceedings 20th World Congress of Dermatology. Paris, France, 2002.
230. Mobacken H. Oral tetracycline - treatment of acne. Rapid facial improvement, but back lesions are more difficult to treat. Lakartidningen. 1993; 90: 2755-2757
231. Leyden J, Thiboutot DM, Shalita AR, Webster G, Washenik K, Strober BE, Shupack J. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol.2006; 142: 605-612
232. Pierard-Franchimont C, Goffin V, Arrese JE, Martalo O, Braham C, Slachmuylders P, Pierard GE. Lymecycline and minocycline in inflammatory acne: a randomized, doubleblind intent-to-treat study on clinical and in vivo antibacterial efficacy. Skin Pharmacol Appl Skin Physiol. 2002; 15: 112-119
233. Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J, Powala C, Ashley R. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003; 139: 459-464
234. Layton AM, Hughes BR, Hull SM, Eady EA, Cunliffe WJ. Seborrhoea - an indicator for poor clinical response in acne patients treated with antibiotics. Clinical and Exp Dermatol. 1992; 17: 173-175
235. Brinkmeier T, Frosch PJ. Oral antibiotics with antiinflammatory/ immunomodulatory effects in the treatment of various dermatoses. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2002; 53: 456-465
236. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006; 54: 258-265
237. Margolis DJ, Bowe WP, Hoffstad O, Berlin JA. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol. 2005; 141: 1132-1136
238. Bowe WP, Hoffstad O, Margolis DJ. Upper respiratory tract infection in household contacts of acne patients. Dermatology. 2007; 215: 213-218
239. Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther. 2007; 32: 483-487
240. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology. 2007; 214: 289-295
241. McManus P, Iheanacho I. Dont use minocycline as first line oral antibiotic in acne. BMJ. Clinical research ed. 2007; 334: 154.
242. ACOG. The use of hormonal contraception in women with coexisting medical conditions. ACOG Prac Bull. 2000; 18: 1-13.
243. Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol. 2002; 46: 917-923
244. Verlag Rote Liste. Rote Liste 2008. Rote Liste Service GmbH, Frankfurt/Main, 2008.
245. Ray AJ, Donskey CJ. Clostridium difficile infection and concurrent vancomycin-resistant Enterococcus stool colonization in a health care worker: case report and review of the literature. Am J Infect Control. 2003; 31: 54-56
246. Cunliffe WJ, Aldana OL, Goulden V. Oral trimethoprim: a relatively safe and successful third-line treatment for acne vulgaris. Br J Dermatol. 1999; 141: 757-758
247. Kawada A, Aragane Y, Tezuka T. Levofloxacin is effective for inflammatory acne and achieves high levels in the lesions: an open study. Dermatology. 2002; 204: 301-302
248. Drlica K, Malik M. Fluoroquinolones: action and resistance. Current topics in medicinal chemistry. 2003; 3: 249-282
249. Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett. 2002; 127: 269-277
250. Mills OH, Jr., Marples RR, Kligman AM. Acne vulgaris. Oral therapy with tetracycline and topical therapy with vitamin A. Arch Dermatol. 1972; 106: 200-203
251. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Arsonnaud S, Kang S. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed. 2005; 4:138-146
252. Gollnick HP, Graupe K, Zaumseil RP. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol. 2001; 11: 538-544
253. Cunliffe WJ. Evolution of a strategy for the treatment of acne. J Am Acad Dermatol. 1987; 16: 591-599
254. Greenwood R, Brummitt L, Burke B, Cunliffe WJ. Acne: double blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment. BMJ. Clinical research ed. 1985; 291: 1231-1235
255. Zouboulis CC, Orfanos C. Retinoids. In: Millikan LE: Drug Therapy in Dermatology. New York, Basel: Marcel Dekker, 2000. 171-233. ISBN: 0824703065.
256. Ganceviciene R, Zouboulis CC. Isotretinoin: state of the art treatment for acne vulgaris. Exp Rev Dermatol. 2007; 2: 693-706.
257. Papakonstantinou E, Aletras AJ, Glass E, Tsogas P, Dionyssopoulos A, Adjaye J, Fimmel S, Gouvousis P, Herwig R, Lehrach H, Zouboulis CC, Karakiulakis G. Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol. 2005; 125: 673-684
258. Zouboulis CC. Isotretinoin revisited: pluripotent effects on human sebaceous gland cells. J Invest Dermatol. 2006; 126: 2154-2156
259. Orfanos CE, Zouboulis CC. Oral retinoids in the treatment of seborrhoea and acne. Dermatology. 1998; 196:140-147
260. Strauss JS, Rapini RP, Shalita AR, Konecky E, Pochi PE, Comite H, Exner JH. Isotretinoin therapy for acne: results of a multicenter doseresponse study. J Am Acad Dermatol. 1984; 10: 490-496
261. Pigatto PD, Finzi AF, Altomare GF, Polenghi MM, Vergani C, Vigotti G. Isotretinoin versus minocycline in cystic acne: a study of lipid metabolism. Dermatologica. 1986; 172: 154-159
262. Prendiville JS, Logan RA, Russell-Jones R. A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne. Clinical and Exp Dermatol. 1988; 13: 67-71.
263. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology. 2003; 206: 37-53.
264. Zouboulis CC. The truth behind this undeniable efficacy - recurrence rates and relapse risk factors of acne treatment with oral isotretinoin. Dermatology.2006; 212: 99-100.
265. Layton AM, Dreno B, Gollnick HP, Zouboulis CC. A review of the European directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol.2006; 20: 773-776
266. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA. 2004; 292:726-735
267. Larsen TH, Jemec GB. Acne: comparing hormonal approaches to antibiotics and isotretinoin. Expert opinion on pharmacotherapy. 2003; 4: 1097-1103
268. Quereux G, Volteau C, NGuyen JM, Dreno B. Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin. Dermatology. 2006; 212: 168-176
269. Arowojolu AO, Gallo MF, Lopez LM, Grims DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane database of systematic reviews (Online), 2009.
270. van Vloten WA, Sigurdsson V. Selecting an oral contraceptive agent for the treatment of acne in women. Am J Clin Dermatol. 2004; 5: 435-441
271. Fotherby K, Caldwell AD. New progestogens in oral contraception. Contraception. 1994; 49: 1-32.
272. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis; cutaneous medicine for the practitioner. 2004; 74: 123-130
273. Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol. 2002; 119: 992-1007.
274. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003; 63: 463-492
275. Fritsch M, Orfanos CE, Zouboulis CC. Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol. 2001; 116:793-800.
276. Gollnick H, Albring M, Brill K. The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type. Ann Endocrinol (Paris). 1999; 60: 157-166
277. Audebert A, Emperaire JC, Gauthier A, Hallonet P, Hedon B, Lopes P, Quereux C, Roulier R. Multicentric clinical trial of a combination of 35 micrograms of ethinylestradiol and 2 mg of cyproterone acetate. Rev Fr Gynecol Obstet. 1991; 86: 697-699
278. Kaiser E. Clinical experience with Diane-35, currently the lowest dose antiandrogenic hormonal ovulation inhibitor, in mild to moderative androgenization in the female. Geburtshilfe Frauenheilkd. 1986; 46:738-742
279. Vartiainen M, de Gezelle H, Broekmeulen CJ. Comparison of the effect on acne with a combiphasic desogestrel- containing oral contraceptive and a preparation containing cyproterone acetate. Eur J Contracept Reprod Health Care. 2001; 6: 46-53.
280. Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum Reprod. 2001; 16:36-42.
281. Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study. Acta Obstet Gynecol Scand Suppl. 1986; 134: 29-32.
282. Lachnit-Fixson U, Kaufmann J. Therapy of androgenization symptoms: double blind study of an antiandrogen preparation (SH B 209 AB) against neogynon (authors transl). Med Klin. 1977; 72: 1922-1926
283. Erkkola R, Hirvonen E, Luikku J, Lumme R, Mannikko H, Aydinlik S. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand. 1990; 69: 61-65
284. Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, Krisanapan O, Benjawang W, Koster A, Doesburg W. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Int J Fertil Menopausal Stud. 1996; 41: 423-429
285. Dieben TO, Vromans L, Theeuwes A, Bennink HJ. The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne. Contraception. 1994; 50: 373-382
286. Aydinlik S, Lachnit-Fixson U, Lehnert J. Reduced estrogen ovulation inhibitor in acne therapy. Double-blind study comparing Diane-35 to Diane. Fortschr Med. 1986; 104: 547-550
287. Colver GB, Mortimer PS, Dawber RP. Cyproterone acetate and two doses of oestrogen in female acne; a double-blind comparison. Br J Dermatol. 1988; 118:95-99
288. Fugere P, Percival-Smith R, Lussier-Cacan S, Tetrault C, Farquhar DJ. The comperative efficacy and safety of Diane-35 versus Diane-50 in the treatment of moderate to severe acne and seborrhea: 12-month results. Recent Res Gynecol Endocrinol.1988; 1: 590-608.
289. Monk BE, Almeyda JA, Caldwell IW, Green B, Pelta D, Leonard J, Du Vivier A, Johnson K, Tolowinska I. Efficacy of low-dose cyproterone acetate compared with minocycline in the treatment of acne vulgaris. Clinical and Exp Dermatol. 1987; 12: 319-322
290. Seaman HE, de Vries CS, Farmer RD. Differences in the use of combined oral contraceptives amongst women with and without acne.Hum Reprod. 2003; 18: 515-521
291. Tan J. Hormonal treatment of acne:Review of current best evidence.J Cut Med Surgery. 2005; 8: 11-15.
292. Kaiser E. Effect of a new hormonal contraceptive (Neo-Eunomin) in females with androgenization symptoms. Geburtshilfe Frauenheilkd.1984; 44: 651-655
293. Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology.2001; 203: 38-44.
294. Moore C, Luderschmidt C, Moltz L, Oettel M, Klinger G, Schreiber G. Antiandrogenic propertiesof the dienogest-containing oral contraceptive Valette. Drugs of Today (Barc). 1999;35: 69-78. (Pubitemid 29342748)
295. Palombo-Kinne E, Schellschmidt I, Schumacher U, Graser T. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.Contraception. 2009; 79: 282-289
296. Foster RH, Wilde MI. Dienogest. Drugs. 1998; 56: 825-33; discussion34-5.
297. Maloney JM, Dietze P, Jr., Watson D, Niknian M, Lee-Rugh S, Sampson-Landers C, Korner P. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol. 2008; 112:773-781
298. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis; cutaneous medicine for the practitioner.2002; 69: 2-15.
299. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000; 43:498-502.
300. Brown J, Farquhar C, Lee O, Toomath R, Jepson RG. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane database of systematic reviews (Online). 2009:CD000194.
301. Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril. 1994; 61: 281-287
302. Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol (Oxf ). 2002; 57: 231-234
303. Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother. 1995; 29: 736-742
304. Wang HS, Wang TH, Soong YK. Low dose flutamide in the treatment of acne vulgaris in women with or without oligomenorrhea or amenorrhea. Changgeng Yi Xue Za Zhi.1999; 22: 423-432
305. Palatsi R, Hirvensalo E, Liukko P, Malmiharju T, Mattila L, Riihiluoma P, Ylostalo P. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta dermato-venereologica. 1984; 64:517-523
306. Upton GV, Corbin A. The relevance of the pharmacologic properties of a progestational agent to its clinical effects as a combination oral contraceptive.Yale J Biol Med. 1989; 62:445-457
307. Leyden J, Shalita A, Hordinsky M, Swinyer L, Stanczyk FZ, Weber ME. Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial. J Am Acad Dermatol. 2002;47: 399-409.
308. Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, Harrison DD. A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril. 2001;76: 461-468
309. Lemay A, Dewailly SD, Grenier R, Huard J. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel. J Clin Endocrinol Metab. 1990; 71: 8-14.
310. Henzl MR. Norgestimate. From the laboratory to three clinical indications. J Reprod Med. 2001; 46:647-661
311. Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol. 1997; 37: 746-754
312. Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol. 1997; 89:615-622
313. Sator PG, Schmidt JB, Honigsmann H. Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris. A pilot study. Dermatology. 2003; 206: 241-248
314. Katz HI, Kempers S, Akin MD, Dunlap F, Whiting D, Norbart TC. Effect of a desogestrel-containing oral contraceptive on the skin. Eur J Contracept Reprod Health Care. 2000; 5: 248-255
315. Vree ML, Schmidt J. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany. Eur J Contracept Reprod Health Care. 2001; 6: 108-114
316. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception. 1999; 60: 321-329
317. Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception. 2004; 69:469-476
318. Rosen MP, Breitkopf DM, Nagamani M. A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. Am J Obstet Gynecol.2003; 188: 1158-1160
319. Pierard-Franchimont C, Gaspard U, Lacante P, Rhoa M, Slachmuylders P, Pierard GE. A quantitative biometrological assessment of acne and hormonal evaluation in young women using a triphasic low-dose oral contraceptive containing gestodene. Eur J Contracept Reprod Health Care.2000; 5: 275-286
320. Halbe HW, de Melo NR, Bahamondes L, Petracco A, Lemgruber M, de Andrade RP, da Cunha DC, Guazelli CA, Baracat EC. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. Eur J Contracept Reprod Health Care. 1998; 3: 113-120
321. Koetsawang S, Charoenvisal C, Banharnsupawat L, Singhakovin S, Kaewsuk O, Punnahitanont S. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women. Contraception.1995; 51: 225-229
322. Mango D, Ricci S, Manna P, Miggiano GA, Serra GB. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception. 1996; 53: 163-170
323. Maloney M, Arbit D, Flack M, McLaughlin-Miley C, Sevilla C, Derman R. Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clin J Womens Health. 2001; 1:124-131
324. Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M, Weber ME. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception. 1999; 60: 255-262
325. Parkin L, Skegg DC, Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet. 2000; 355: 2133-2134
326. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.Lancet. 2001; 358: 1427-1429 (Pubitemid 33055749)
327. Mant J, Painter R, Vessey M. Risk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study. Br J Obstet Gynaecol. 1998; 105:890-896
328. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. Clinical research ed.2009; 339: b2890.
329. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. Clinical research ed.2009; 339: b2921.
330. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75: 344-354
331. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol. 2007; 110: 587-593
332. Ross CM. The treatment of acne vulgaris with dapsone. Br J Dermatol. 1961; 73: 367-370
333. Tan BB, Lear JT, Smith AG. Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. Clinical and Exp Dermatol. 1997; 22: 26-27
334. Hofer T, Itin PH. Acne inversa: a dapsone-sensitive dermatosis. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2001; 52: 989-992
335. Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: A case series of five patients. The Journal of dermatological treatment. 2006; 17: 211-213
336. Bolz S, Jappe U, Hartschuh W. Successful treatment of perifolliculitis capitis abscedens et suffodiens with combined isotretinoin and dapsone. J Dtsch Dermatol Ges. 2008; 6: 44-47
337. Bojar RA, Eady EA, Jones CE, Cunliffe WJ, Holland KT. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol. 1994; 130:329-336
338. Fluhr JW, Bosch B, Gloor M, Hoffler U. In-vitro and in-vivo efficacy of zinc acetate against propionibacteria alone and in combination with
339. Lutz GA. Zinksalze. In: Korting HC, Sterry W: Therapeutische Verfahren in der Dermatologie: Dermatika und Kosmetika. Berlin: Blackwell, 2001. 607-614
340. Nitzan YB, Cohen AD. Zinc in skin pathology and care. J Dermatol Treat. 2006; 17: 205-210
341. Dreno B, Amblard P, Agache P, Sirot S, Litoux P. Low doses of zinc luconate for inflammatory acne. Acta dermato-venereologica. 1989; 69: 541-543
342. Goransson K, Liden S, Odsell L. Oral zinc in acne vulgaris: a clinical and methodological study. Acta dermatovenereologica. 1978; 58: 443-448
343. Hillstrom L, Pettersson L, Hellbe L, Kjellin A, Leczinsky CG, Nordwall C. Comparison of oral treatment with zinc sulphate and placebo in acne vulgaris. Br J Dermatol. 1977;97: 681-684
344. Michaelsson G, Juhlin L, Vahlquist A. Effects of oral zinc and vitamin A in acne. Arch Dermatol. 1977; 113: 31-36 (Pubitemid 8020125)
345. Verma KC, Saini AS, Dhamija SK. Oral zinc sulphate therapy in acne vulgaris: a double-blind trial. Acta dermato-venereologica. 1980; 60:337-340
346. Weimar VM, Puhl SC, Smith WH, tenBroeke JE. Zinc sulfate in acne vulgaris. Arch Dermatol. 1978; 114: 1776-1778
347. Orris L, Shalita AR, Sibulkin D, London SJ, Gans EH. Oral zinc therapy of acne. Absorption and clinical effect. Arch Dermatol. 1978; 114:1018-1020
348. Weismann K, Wadskov S, Sondergaard J. Oral zinc sulphate therapy for acne vulgaris. Acta dermato-venereologica. 1977; 57: 357-360
349. Dreno B, Moyse D, Alirezai M, Amblard P, Auffret N, Beylot C, Bodokh I, Chivot M, Daniel F, Humbert P, Meynadier J, Poli F. Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Dermatology. 2001; 203:135-140
350. Michaelsson G, Juhlin L, Ljunghall K. A double-blind study of the effect of zinc and oxytetracycline in acne vulgaris. Br J Dermatol. 1977; 97:561-566
351. Cunliffe WJ, Burke B, Dodman B, Gould DJ. A double-blind trial of a zinc sulphate/citrate complex and tetracycline in the treatment of acne vulgaris. Br J Dermatol. 1979; 101:321-325
352. Borelli C, Merk K, Plewig G, Degitz K. Light, laser and PDT therapy for acne. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2005; 56: 1027-1032
353. Degitz K. Phototherapy, photodynamic therapy and lasers in the treatment of acne. J Dtsch Dermatol Ges.2009; 7: 1048-1053
354. Thiboutot D, Gollnick H, Bettoli V, Dreno B, Kang S, Leyden JJ, Shalita AR, Lozada VT, Berson D, Finlay A, Goh CL, Herane MI, Kaminsky A, Kubba R, Layton A, Miyachi Y, Perez M, Martin JP, Ramos ESM, See JA, Shear N, Wolf J, Jr. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009; 60: S1-50.
355. Meffert H, Kolzsch J, Laubstein B, Sonnichsen N. Phototherapy of acne vulgaris with the "TuR" UV 10 body section irradiation unit. Dermatologische Monatschrift. 1986; 172:9-13.
356. Mills OH, Kligman AM. Ultraviolet phototherapy and photochemotherapy of acne vulgaris. Arch Dermatol. 1978; 114: 221-223
357. Mills OH, Porte M, Kligman AM. Enhancement of comedogenic substances by ultraviolet radiation. Br J Dermatol. 1978; 98: 145-150
358. Motoyoshi K. Enhanced comedo formation in rabbit ear skin by squalene and oleic acid peroxides. Br J Dermatol. 1983; 109: 191-198
359. Papageorgiou P, Chu AC. Chloroxylenol and zinc oxide containing cream (Nels cream) vs. 5% benzoyl peroxide cream in the treatment of acne vulgaris. A doubleblind, randomized, controlled trial.Clinical and Exp Dermatol. 1999; 25: 16-25.
360. Tzung TY, Wu KH, Huang ML. Blue light phototherapy in the treatment of acne. Photodermatol Photoimmunol Photomed. 2004; 20: 266-269
361. Gold MH. Acne vulgaris: lasers, light sources and photodynamic therapy -an update 2007. Expert review of anti-infective therapy. 2007; 5: 1059-1069
362. Akaraphanth R, Kanjanawanitchkul W, Gritiyarangsan P. Efficacy of ALAPDT vs blue light in the treatment of acne. Photodermatol Photoimmunol Photomed. 2007; 23: 186-190
363. Hong SB, Lee MH. Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris. Photodermatol Photoimmunol Photomed. 2005; 21: 322-325
364. Hongcharu W, Taylor CR, Chang Y, Aghassi D, Suthamjariya K, Anderson RR. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol. 2000; 115:183-192
365. Horfelt C, Funk J, Frohm-Nilsson M, Wiegleb Edstrom D, Wennberg AM. Topical methyl aminolaevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. Br J Dermatol. 2006; 155: 608-613
366. Pollock B, Turner D, Stringer MR, Bojar RA, Goulden V, Stables GI, Cunliffe WJ. Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action. Br J Dermatol. 2004; 151:616-622
367. Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using 5- aminolevulinic acid versus methyl aminolevulinate. J Am Acad Dermatol. 2006; 54: 647-651
368. Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methyl aminolaevulinate: a blinded, randomized, controlled trial. Br J Dermatol. 2006; 154: 969-976
369. Rojanamatin J, Choawawanich P. Treatment of inflammatory facial acne vulgaris with intense pulsed light and short contact of topical 5-aminolevulinic acid: a pilot study. Dermatol Surg. 2006; 32: 991-6; discussion 96-97
370. Haedersdal M, Togsverd-Bo K, Wiegell SR, Wulf HC. Long-pulsed dye laser versus long-pulsed dye laserassisted photodynamic therapy for acne vulgaris: A randomized controlled trial. J Am Acad Dermatol. 2008; 58: 387-394
371. Santos MA, Belo VG, Santos G. Effectiveness of photodynamic therapy with topical 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone in the treatment of acne vulgaris: comparative study. Dermatol Surg. 2005; 31: 910-915
372. Seaton ED, Charakida A, Mouser PE, Grace I, Clement RM, Chu AC. Pulsed-dye laser treatment for inflammatory acne vulgaris: randomized controlled trial. Lancet. 2003; 362: 1347-1352
373. Orringer JS, Kang S, Hamilton T, Schumacher W, Cho S, Hammerberg C, Fisher GJ, Karimipour DJ, Johnson TM, Voorhees JJ. Treatment of acne vulgaris with a pulsed dye laser: a randomized controlled trial. Jama.2004; 291: 2834-2839 (Pubitemid 38747803)
374. Baugh WP, Kucaba WD. Nonablative phototherapy for acne vulgaris using the KTP 532 nm laser. Dermatol Surg. 2005; 31: 1290-1296
375. Paithankar DY, Ross EV, Saleh BA, Blair MA, Graham BS. Acne treatment with a 1,450 nm wavelength laser and cryogen spray cooling. Lasers Surg Med. 2002; 31: 106-114
376. Wang SQ, Counters JT, Flor ME, Zelickson BD. Treatment of inflammatory facial acne with the 1,450 nm diode laser alone versus microdermabrasion plus the 1,450 nm laser: a randomized, split-face trial. Dermatol Surg. 2006; 32: 249-55;discussion 55.
377. Thiboutot D, Pariser DM, Egan N, Flores J, Herndon JH, Jr., Kanof NB, Kempers SE, Maddin S, Poulin YP, Wilson DC, Hwa J, Liu Y, Graeber M. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol.2006; 54: 242-250
378. Alirezai M, George SA, Coutts I, Roseeuw DI, Hachem JP, Kerrouche N, Sidou F, Soto P. Daily treatment with adapalene gel 0.1% maintains initial improvement of acne vulgaris previously treated with oral lymecycline. Eur J Dermatol. 2007; 17: 45-51.
379. Toombs EL. Cosmetics in the treatment of acne vulgaris. Dermatol Clin. 2005; 23: 575-81, viii.
380. Korting HC, Ponce-Poschl E, Klovekorn W, Schmotzer G, Arens-Corell M, Braun-Falco O. The influence of the regular use of a soap or an acidic syndet bar on pre-acne. Infection. 1995; 23: 89-93.
381. Scherdin U, Presto S, Rippke F, Nielsen J, Strassner M, Imadojemun A, Gartner E, Herpens A, Korting HC, Bielfeldt S. In vivo assessment of the efficacy of an innovative face care system in subjects with mild acne vulgaris. Int J Cosmet Sci. 2004; 26:221-229
382. Boehncke WH, Ochsendorf F, Paeslack I, Kaufmann R, Zollner TM. Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases. Eur J Dermatol. 2002; 12: 577-580
383. Briden ME. Alpha-hydroxyacid chemical peeling agents: case studies and rationale for safe and effective use. Cutis; cutaneous medicine for the practitioner. 2004; 73: 18-24.
384. Kim TH, Choi EH, Kang YC, Lee SH, Ahn SK. The effects of topical alpha- hydroxyacids on the normal skin barrier of hairless mice. Br J Dermatol. 2001; 144: 267-273
385. Ditre CM, Griffin TD, Murphy GF, Sueki H, Telegan B, Johnson WC, Yu RJ, Van Scott EJ. Effects of alpha-hydroxy acids on photoaged skin: a pilot clinical, histologic, and ultrastructural study. J Am Acad Dermatol. 1996; 34: 187-195
386. Atzori L, Brundu MA, Orru A, Biggio P. Glycolic acid peeling in the treatment of acne. J Eur Acad Dermatol Venereol. 1999; 12: 119-122
387. Grover C, Reddu BS. The therapeutic value of glycolic acid peels in dermatology. Indian J Dermatol Venereol Leprol. 2003; 69: 148-150
388. Lee SH, Huh CH, Park KC, Youn SW. Effects of repetitive superficial chemical peels on facial sebum secretion in acne patients. J Eur Acad Dermatol Venereol. 2006; 20: 964-968
389. Ahn HH, Kim IH. Whitening effect of salicylic acid peels in Asian patients. Dermatol Surg. 2006; 32: 372-5; discussion 75.
390. Kempiak SJ, Uebelhoer N. Superficial chemical peels and microdermabrasion for acne vulgaris. Semin Cutan Med Surg. 2008; 27: 212-220
391. Yokoyama A, Takakubo F, Eto K, Ueno K, Igarashi T, Satoh T, Kitagawa H. Teratogenicity of aspirin and its metabolite, salicylic acid, in cultured rat embryos. Res Commun Chem Pathol Pharmacol. 1984; 46: 77-91.
392. Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol. 2003; 4: 473-492
393. Kessler E, Flanagan K, Chia C, Rogers C, Glaser DA. Comparison of alpha-and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. Dermatol Surg. 2008; 34: 45-50; discussion 51.
394. Kligman D, Kligman AM. Salicylic acid as a peeling agent for the treatment of acne. Cosmetic Dermatol. 1997; 10: 44-47
395. Wiest L. Chemical peels in aesthetic dermatology. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2004; 55: 611-620
396. Goodman GJ. Post-acne scarring: a short review of its pathophysiology. Australas J Dermatol. 2001; 42: 84-90.
397. Bock O, Schmid-Ott G, Malewski P, Mrowietz U. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res. 2006; 297: 433-438
398. Jacob CI, Dover JS, Kaminer MS. Acne scarring: a classification system and review of treatment options. J Am Acad Dermatol. 2001; 45:109-117
399. Orentreich DS, Orentreich N. Subcutaneous incisionless (subcision) surgery for the correction of depressed scars and wrinkles. Dermatol Surg. 1995; 21: 543-549
400. Alam M, Omura N, Kaminer MS. Subcision for acne scarring: technique and outcomes in 40 patients.Dermatol Surg. 2005; 31: 310-7; discussion 17.
401. Balighi K, Robati RM, Moslehi H, Robati AM. Subcision in acne scar with and without subdermal implant: a clinical trial. J Eur Acad Dermatol Venereol. 2008; 22: 707-711
402. Jordan R, Cummins C, Burls A. Laser resurfacing of the skin for the improvement of facial acne scarring: a systematic review of the evidence. Br J Dermatol. 2000; 142: 413-423
403. Alster TS, West TB. Resurfacing of atrophic facial acne scars with a highenergy, pulsed carbon dioxide laser. Dermatol Surg. 1996; 22: 151-4; discussion 54-55
404. Walia S, Alster TS. Prolonged clinical and histologic effects from CO2 laser resurfacing of atrophic acne scars. Dermatol Surg. 1999; 25: 926-930
405. Jeong JT, Kye YC. Resurfacing of pitted facial acne scars with a long-pulsed Er:YAG laser. Dermatol Surg. 2001; 27: 107-110
406. Rostan EF, Fitzpatrick RE, Goldman MP. Laser resurfacing with a long pulse erbium:YAG laser compared to the 950 ms pulsed CO(2) laser. Lasers Surg Med. 2001; 29: 136-141
407. Weinstein C. Modulated dual mode erbium/CO2 lasers for the treatment of acne scars. Journal of cutaneous laser therapy. 1999; 1: 204-208
408. Chapas AM, Brightman L, Sukal S, Hale E, Daniel D, Bernstein LJ, Geronemus RG. Successful treatment of acneiform scarring with CO2 ablative fractional resurfacing. Lasers Surg Med. 2008; 40: 381-386
409. Walgrave SE, Ortiz AE, MacFalls HT, Elkeeb L, Truitt AK, Tournas JA, Zelickson BD, Zachary CB. Evaluation of a novel fractional resurfacing device for treatment of acne scarring. Lasers Surg Med. 2009; 41: 122-127
410. Bellew SG, Lee C, Weiss MA, Weiss RA. Improvement of atrophic acne scars with a 1,320 nm Nd:YAG laser: retrospective study. Dermatol Surg. 2005; 31: 1218-21; discussion 22.
411. Bhatia AC, Dover JS, Arndt KA, Stewart B, Alam M. Patient satisfaction and reported long-term therapeutic efficacy associated with 1,320 nm Nd:YAG laser treatment of acne scarring and photoaging. Dermatol Surg. 2006; 32: 346-352
412. Chan HH, Lam LK, Wong DS, Kono T, Trendell-Smith N. Use of 1,320 nm Nd:YAG laser for wrinkle reduction and the treatment of atrophic acne scarring in Asians. Lasers Surg Med. 2004; 34: 98-103.
413. Friedman PM, Jih MH, Skover GR, Payonk GS, Kimyai-Asadi A, Geronemus RG. Treatment of atrophic facial acne scars with the 1064-nm Q-switched Nd:YAG laser: six-month follow-up study. Arch Dermatol. 2004; 140: 1337-1341
414. Keller R, Belda Junior W, Valente NY, Rodrigues CJ. Nonablative 1,064-nm Nd:YAG laser for treating atrophic facial acne scars: histologic and clinical analysis. Dermatol Surg. 2007; 33: 1470-1476
415. Lipper GM, Perez M. Nonablative acne scar reduction after a series of treatments with a short-pulsed 1,064-nm neodymium:YAG laser. Dermatol Surg. 2006; 32: 998-1006.
416. Sadick NS, Schecter AK. A preliminary study of utilization of the 1320-nm Nd:YAG laser for the treatment of acne scarring. Dermatol Surg. 2004; 30: 995-1000.
417. Tanzi EL, Alster TS. Comparison of a 1450-nm diode laser and a 1320-nm Nd:YAG laser in the treatment of atrophic facial scars: a prospective clinical and histologic study. Dermatol Surg. 2004; 30: 152-157
418. Yaghmai D, Garden JM, Bakus AD, Massa MC. Comparison of a 1,064 nm laser and a 1,320 nm laser for the nonablative treatment of acne scars. Dermatol Surg. 2005; 31: 903-909
419. Chua SH, Ang P, Khoo LS, Goh CL. Nonablative 1450-nm diode laser in the treatment of facial atrophic acne scars in type IV to V Asian skin: a prospective clinical study. Dermatol Surg. 2004; 30: 1287-1291
420. Alster TS, McMeekin TO. Improvement of facial acne scars by the 585 nm flashlamp-pumped pulsed dye laser. J Am Acad Dermatol. 1996; 35:79-81.
421. Alster TS, Tanzi EL, Lazarus M. The use of fractional laser photothermolysis for the treatment of atrophic scars. Dermatol Surg. 2007; 33: 295-299
422. Chrastil B, Glaich AS, Goldberg LH, Friedman PM. Second-generation 1,550-nm fractional photothermolysis for the treatment of acne scars. Dermatol Surg. 2008; 34: 1327-1332
423. Erol OO, Gurlek A, Agaoglu G, Topcuoglu E, Oz H. Treatment of hypertrophic scars and keloids using intense pulsed light (IPL). Aesthetic Plast Surg. 2008; 32: 902-909
424. Lee JB, Chung WG, Kwahck H, Lee KH. Focal treatment of acne scars with trichloroacetic acid: chemical reconstruction of skin scars method. Dermatol Surg. 2002; 28: 1017-21;discussion 21.
425. Sadick NS, Hudgins LC. Fatty acid analysis of transplanted adipose tissue. Arch Dermatol. 2001; 137: 723-727
426. Tsai RY, Wang CN, Chan HL. Aluminum oxide crystal microdermabrasion. A new technique for treating facial scarring. Dermatol Surg. 1995; 21: 539-542
427. Koller J, Sebastian G. Therapy for pathologic scars (hypertrophic scars and keloids). J Dtsch Dermatol Ges.2004; 2: 308-312
428. Balina LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991; 30: 893-895
429. Romero C, Aberdam E, Larnier C, Ortonne JP. Retinoic acid as modulator of UVB-induced melanocyte differentiation. Involvement of the melanogenic enzymes expression. J Cell Sci. 1994; 107 ( Pt 4): 1095-1103
430. Dogra S, Kanwar AJ, Parsad D. Adapalene in the treatment of melasma: a preliminary report. J Dermatol. 2002; 29: 539-540
431. Burns RL, Prevost-Blank PL, Lawry MA, Lawry TB, Faria DT, Fivenson DP. Glycolic acid peels for postinflammatory hyperpigmentation in black patients. A comparative study. Dermatol Surg. 1997; 23: 171-4; discussion 75.
432. Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg. 1999; 25: 18-22.
433. Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. J Am Acad Dermatol. 2008; 58: 719-37;quiz 38-40.
434. Watanabe S. Basics of laser application to dermatology. Arch Dermatol Res. 2008; 300 Suppl 1: S21-30.
435. Bogle MA. Fractionated mid-infrared resurfacing. Semin Cutan Med Surg. 2008; 27: 252-258
436. Rokhsar CK, Fitzpatrick RE. The treatment of melasma with fractional photothermolysis: a pilot study. Dermatol Surg. 2005; 31: 1645-1650
437. Karsai S, Raulin C. Fractional photothermolysis: a new option for treating melasma? Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2008; 59: 92-100.
438. Seppala H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, Huovinen P. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med. 1997;337: 441-446
439. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol. 1989;121: 51-57
440. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol. 2005; 153: 395-403.
441. Nord CE, Oprica C. Antibiotic resistance in Propionibacterium acnes. Microbiological and clinical aspects. Anaerobe. 2006; 12: 207-210
442. Mills O, Jr., Thornsberry C, Cardin CW, Smiles KA, Leyden JJ. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta dermatovenereologica. 2002; 82: 260-265
443. Levy RM, Huang EY, Roling D, Leyden JJ, Margolis DJ. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol. 2003; 139: 467-471
444. Oprica C, Emtestam L, Hagstromer L, Nord CE. Clinical and microbiological comparisons of isotretinoin vs. tetracycline in acne vulgaris. Acta dermato- venereologica. 2007; 87: 246-254
445. Ozolins M, Eady EA, Avery A, Cunliffe WJ, ONeill C, Simpson NB, Williams HC. Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. Health technology assessment (Winchester, England).2005; 9: iii-212.
446. Oprica C, Nord CE. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes. Clin Microbiol Infect. 2005; 11: 204-213
447. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clinical and Exp Dermatol. 1994; 19: 210-216
448. Augustin M, Wenninger K, Amon U, Schroth MJ, Kuster W, Chren M, Kupfer J, Gieler U. German adaptation of the Skindex-29 questionnaire on quality of life in dermatology: validation and clinical results. Dermatology. 2004; 209: 14-20.
449. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997; 133:1433-1440
450. Anderson RT, Aaronson NK, Bullinger M, McBee WL. A review of the progress towards developing healthrelated quality-of-life instruments for international clinical studies and outcomes research. Pharmacoeconomics. 1996; 10: 336-355
451. Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales - a measure of the impact of skin diseases. Br J Dermatol. 1997; 136: 202-206
452. Rothmann KF, Pochi PE. Use of oral and topical agents for acne in pregnancy. J Am Acad Dermatol. 1988;19: 431-442
453. Barza M, Goldstein JA, Kane A, Feingold DS, Pochi PE. Systemic absorption of clindamycin hydrochloride after topical application. J Am Acad Dermatol. 1982; 7: 208-214
454. Borglund E, Hagermark O, Nord CE. Impact of topical clindamycin and systemic tetracycline on the skin and colon microflora in patients with acne vulgaris. Scand J Infect Dis. 1984; 43: 76-81.
455. Becker LE, Bergstresser PR, Whiting DA, Clendenning WE, Dobson RL, Jordan WP, Abell E, LeZotte LA, Pochi PE, Shupack JL, Sigafoes RB, Stoughton RB, Voorhees JJ. Topical clindamycin therapy for acne vulgaris. A cooperative clinical study. Arch Dermatol. 1981; 117: 482-485
456. Milstone EB, McDonald AJ, Scholhamer CF, Jr. Pseudomembranous colitis after topical application of clindamycin. Arch Dermatol. 1981; 117: 154-155
457. Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol. 1986; 122: 583-584
458. Worret WI, Fluhr JW. Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. J Dtsch Dermatol Ges. 2006; 4: 293-300.
459. Kretschmar R, Leuschner F. Investigation on the toxicity of tretinoin administered systemically to animals. Acta Derm Venereol Suppl (Stockh). 1975; 74: 25-28
460. van Hoogdalem EJ. Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J Eur Acad Dermatol Venereol. 1998; 11 Suppl 1: S13-9;discussion S28-9.
461. Nau H. Embryotoxicity and teratogenicity of topical retinoic acid. Skin Pharmacol. 1993; 6 Suppl 1:35-44.
462. Krautheim A, Gollnick H. Transdermal penetration of topical drugs used in the treatment of acne. Clin Pharmacokinet. 2003; 42: 1287-1304
463. Duran B, Gursoy S, Cetin M, Demirkoprulu N, Demirel Y, Gurelik B. The oral toxicity of resorcinol during pregnancy: a case report. Journal of toxicology. 2004; 42: 663-666
464. Thiboutot DM. Overview of acne and its treatment. Cutis; cutaneous medicine for the practitioner. 2008;81: 3-7.
465. Hale EK, Pomeranz MK. Dermatologic agents during pregnancy and lactation: an update and clinical review. Int J Dermatol. 2002; 41:197-203.
466. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998; 338: 1128-1137
467. Morsches B, Holzmann H. Studies on the percutaneous absorption of benzoyl peroxide (authors transl). Arzneimittel-Forschung. 1982; 32:298-300.
468. Nacht S, Yeung D, Beasley JN, Jr., Anjo MD, Maibach HI. Benzoyl peroxide: percutaneous penetration and metabolic disposition. J Am Acad Dermatol. 1981; 4: 31-37
469. Cunliffe WJ, Gollnick HPF, Orfanos CE. Akne. Hippokrates Verlag, Stuttgart,1993. ISBN: 1841844047.
470. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR, Thiboutot D. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003; 49 Suppl 1: S1-37.
471. Tauber U, Weiss C, Matthes H. Percutaneous absorption of azelaic acid in humans. Exp Dermatol. 1992; 1:176-179
472. Cooper WO, Griffin MR, Arbogast P, Hickson GB, Gautam S, Ray WA. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med. 2002; 156: 647-650
473. Weinstein AJ, Gibbs RS, Gallagher M. Placental transfer of clindamycin and gentamicin in term pregnancy. Am J Obstet Gynecol. 1976; 124:688-691
474. McCormack WM, George H, Donner A, Kodgis LF, Alpert S, Lowe EW, Kass EH. Hepatotoxicity of erythromycin estolate during pregnancy. Antimicrob Agents Chemother. 1977; 12: 630-635
475. Gallagher JC, Ismail MA, Aladjem S. Reduced urinary estriol levels with erythromycin therapy. Obstet Gynecol. 1980; 56: 381-382
476. Dreno B, Blouin E. Acne, pregnant women and zinc salts: a literature review. Ann Dermatol Venerol. 2008;135: 27-33.
477. Stephan F, Revuz J. Zinc salts in dermatology. Ann Dermatol Venerol. 2004; 131: 455-460